| Literature DB >> 32424505 |
Kornelia Czaja1, Jacek Kujawski2, Karol Kamel3, Marek K Bernard2.
Abstract
Protein kinases control diversity of biochemical processes in human organism. Checkpoint 1 kinase (Chk1) is an important element of the checkpoint signalling pathways and is responsible for DNA damage repair. Hence, this kinase plays an essential role in cancer cells survival and has become an important target for anticancer agents. Our previous investigations showed that some arylsulphonyl indazole derivatives displayed anticancer effect in vitro. In the present study, in order to verify possibility of interactions of pyrazole and indazole derivatives with Chk1, we focused on the docking of selected tosyl derivatives of indazole and condensed pyrazole 1-7 to the Chk1 pocket, analysis of interactions involving optimized ligand-protein system using DFT formalism, and estimation of the interaction enthalpy of the ligand-protein complex by applying the PM7 method. The estimation of binding affinity seems to indicate that the indazole 5-substituted with 3,5-dimethylpyrazole 4 and condensed pyrazoloquinoline derivative 7 fit the best to the Chk1-binding pocket. The values of the energy of interaction, i.e. the enthalpy change (ΔHint), were between - 85.06 and - 124.04 kcal mol-1 for the optimized ligand-Chk1 complexes. The relaxation of the ligands within the complexes azole-protein as well as the distribution of hydrogen contacts between the ligands and kinase pocket amino acids was also analysed using molecular dynamics as a supporting method. Graphical Abstract Presentation of methods used to describe the interactions between arylsulphonyl pyrazole derivatives and Chk1 kinase.Entities:
Keywords: Azoles; Checkpoint kinase 1; DFT calculations; Docking; Hydrogen bond; Kinases; Molecular dynamics
Mesh:
Substances:
Year: 2020 PMID: 32424505 PMCID: PMC7235069 DOI: 10.1007/s00894-020-04407-3
Source DB: PubMed Journal: J Mol Model ISSN: 0948-5023 Impact factor: 1.810
Scheme 1The investigated azoles as potential Chk1 kinase ligands
Fig. 1Superimposition of docked azoles 1–7 (1st poses, MGLTools 1-5-6 program)
Fig. 2Docking poses of azoles 1–7 (1st poses)
Ligand-amino acid distances (Å) between azoles 1–7 and amino acid residues within a 4-Å sphere around the ligand after ligand optimization with B3LYP/6-31G(d,p) method; RMSDcomplex = 0.351 (1), 0.382 (2), 0.505 (3), 0.485 (4), 0.470 (5), 0.743 (6), 0.893 (7) Å, respectively; the corresponding contact distances for the ligands docked to 2e9n.pdbqt were given in brackets
| Contacts | Distances calculated for optimized azoles | ||||||
|---|---|---|---|---|---|---|---|
| N-H…O=CGlu85 | 2.841 | 2.854 | 3.077 | 2.826 | ☓ | ☓ | 2.630 |
| SO2…H-OSer147 | 2.517 | 2.500 | 3.266 | 2.817 | ☓ | ☓ | 2.961 |
| N2indol…O-HTyr20 | ☓ | ☓ | ☓ | ☓ | 3.063 | ☓ | ☓ |
| N-H…OOCAsp148 | ☓ | ☓ | ☓ | ☓ | 3.787 (7.115) | ☓ | ☓ |
| N-H…OSer147 | ☓ | ☓ | ☓ | ☓ | ☓ | 3.514 | ☓ |
| N-H…OGlu17 | ☓ | ☓ | ☓ | ☓ | 3.787 (3.309) | ☓ | ☓ |
Ligand-amino acid distances (Å) between azoles 1–7 and amino acid residues within a 4-Å sphere around the ligand after ligand optimization with B3LYP/6-31G(d,p) method; RMSDcomplex = 0.337 (1), 0.368 (2), 0.423 (3), 0.484 (4), 0.337 (5), 0.748 (6), 1.070 (7) Å; the contacts resulted from the docking procedure are given in brackets
| Contacts | Distances calculated for optimized azoles | ||||||
|---|---|---|---|---|---|---|---|
| N-H…O=CGlu85 | 2.866 | 2.926 | 2.661 | 2.871 | ☓ | ☓ | 2.654 |
| SO2…H-OSer147 | 2.644 | 2.593 | 3.377 | 2.791 | ☓ | ☓ | 2.846 |
| SO2…H-NLys38 | ☓ | ☓ | ☓ | ☓ | 3.060 | ☓ | ☓ |
| N2indol…O-HTyr20 | ☓ | ☓ | ☓ | ☓ | 2.402 | ☓ | ☓ |
| N-H…OOCAsp148 | ☓ | ☓ | ☓ | ☓ | 3.330 (7.115) | ☓ | ☓ |
| N-H…OSer147 | ☓ | ☓ | ☓ | ☓ | ☓ | 3.503 | ☓ |
| N-H…OGlu17 | ☓ | ☓ | ☓ | ☓ | 3.330 (3.309) | ☓ | ☓ |
Ligand-amino acid distances (Å) between azoles 1–7 and residues within a 4-Å sphere around the ligand after ligand optimization with PM7 method; RMSDcomplex = 0.130 (1), 0.127 (2), 0.138 (3), 0.119 (4), 0.292 (5), 0.143 (6), 0.157 (7) Å, respectively; the contacts resulted from the docking procedure are given in brackets
| Contacts | Distances calculated for optimized azoles | ||||||
|---|---|---|---|---|---|---|---|
| N-H…O=CGlu85 | 2.432 | 1.974 | 2.060 | 2.047 | ☓ | ☓ | 2.493 |
| SO2…H-OSer147 | 5.774 | 5.409 | 5.371 | 5.089 | ☓ | ☓ | 5.386 |
| SO2…H-NLys38 | 2.947 (4.037) | 3.478 (4.054) | 3.352 (3.937) | 3.492 (4.053) | 1.699 | 1.591 (4.303) | 2.953 (3.970) |
| N2indol…H-NLys38 | ☓ | ☓ | ☓ | ☓ | 3.157 (5.320) | ☓ | ☓ |
| N2indol…O-HTyr20 | ☓ | ☓ | ☓ | ☓ | 5.624 | ☓ | ☓ |
| N-H…OOCAsp148 | ☓ | ☓ | ☓ | ☓ | 1.861 (7.115) | ☓ | ☓ |
| N-H…O=CAsn135 | ☓ | ☓ | ☓ | ☓ | ☓ | 2.584 | ☓ |
| N2…H-OSer147 | ☓ | ☓ | ☓ | ☓ | ☓ | 3.556 | ☓ |
Ligand-amino acid distances (including hydrogen bonds) (Å) between azoles 1–7 and residues within a 4-Å sphere around the ligand after ligand optimization with PM7 method; RMSDcomplex = 0.604 (1), 1.085 (2), 0.622 (3), 1.438 (4), 0.790 (5), 0.058 (6), 0.689 (7) Å, respectively; the contacts resulted from the docking procedure are given in brackets
| Contacts | Contacts length calculated for optimized azoles | ||||||
|---|---|---|---|---|---|---|---|
| N-H…O=CGlu85 | 1.841 | 1.913 | 1.855 | 1.793 | ☓ | ☓ | 3.244 |
| SO2…H-OSer147 | 2.919 | 4.406 | 3.257 | 3.754 | ☓ | ☓ | 1.792 |
| SO2…H-NLys38 | ☓ | ☓ | ☓ | ☓ | 2.475 | ☓ | 4.155 (3.970) |
| N2indol…H-NLys38 | ☓ | ☓ | ☓ | ☓ | 4.289 (5.320) | ☓ | ☓ |
| N2indol…O-HTyr20 | ☓ | ☓ | ☓ | ☓ | 3.758 | ☓ | ☓ |
| N-H…OO=CAsp148 | ☓ | ☓ | ☓ | ☓ | 4.870 (7.115) | ☓ | ☓ |
| N-H…O=CAsn135 | ☓ | ☓ | ☓ | ☓ | ☓ | 1.750 | ☓ |
| N2…H-OSer147 | ☓ | ☓ | ☓ | ☓ | ☓ | 4.565 | ☓ |
| N-H…OGlu17 | ☓ | ☓ | ☓ | ☓ | 3.486 (3.309) | ☓ | ☓ |
Calculated heats of formations (kcal mol−1) for free ligands (ΔHfcomplex(L)), free protein (ΔHfcomplex(P)), ligand–protein complex (ΔHf(PL)), as well as ligand–protein interaction energy (ΔHint)
| Compound | HOF of ligand (Δ | HOF of protein (Δ | HOF of complex (Δ | Δ |
|---|---|---|---|---|
| 1 | − 1.11 | − 1164.89 | − 1251.06 | − 85.06 |
| 2 | 43.41 | − 2046.66 | − 2105.93 | − 102.67 |
| 3 | 62.88 | − 1370.37 | − 1405.87 | − 98.39 |
| 4 | 46.76 | − 2130.38 | − 2207.67 | − 124.04 |
| 5 | 55.48 | − 1844.07 | − 1900.47 | − 111.88 |
| 6 | 49.99 | − 1673.68 | − 1723.83 | − 100.14 |
| 7 | 34.23 | − 1212.30 | − 1276.91 | − 92.18 |
Fig. 3The RMSD plot for the backbone within ligand–protein complex during the productive phase calculated for free kinase (black), as well as its complex with the following: 1 (red), 2 (green), 3 (blue), 4 (yellow), 5 (grey), 6 (light grey), and 7 (purple)